Tanaka Y, et al. - Researchers investigated what extent of remission offers the greatest predictability of maintaining remission after etanercept dose reduction or discontinuation in patients with rheumatoid arthritis (RA). For this purpose, they used data from three etanercept down-titration studies involving RA patients with moderate to severe disease: PRESERVE, PRIZE, and Treat-to-Target randomized controlled trials. They found that the likelihood of remaining in remission or low disease activity after etanercept dose reduction or withdrawal was higher in patients attaining disease control according to a stringent definition, such as sustained American College of Rheumatology/European League Against Rheumatism Boolean or clinical disease activity index remission, or a new definition of sustained deep remission by Disease Activity Score 28-joints.